Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 4, 2012, Pages 1411-1416

  Nguyen, Paul L ^a   Chen, Ming Hui ^b   Beckman, Joshua A ^a   Beard, Clair J ^a   Martin, Neil E ^a   Choueiri, Toni K ^g   Hu, Jim C ^h   Hoffman, Karen E ^c   Dosoretz, Daniel E ^d   Moran, Brian J ^e   Salenius, Sharon A ^d   Braccioforte, Michelle H ^e   Kantoff, Philip W ^g   D'Amico, Anthony V ^a   Ennis, Ronald D ^f  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d 21ST CENTURY ONCOLOGY   (United States)

^e Chicago Prostate Center   (United States)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Androgen deprivation therapy; Cardiovascular; Mortality; Prostate cancer

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; CARDIOVASCULAR; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURES; EXTERNAL BEAM RADIATION; HAZARD RATIO; HIGH-RISK PATIENTS; IN-PHASE; MORTALITY; MULTIVARIABLE ANALYSIS; MYOCARDIAL INFARCTION; OVERALL SURVIVAL; PROGNOSTIC FACTORS; PROPENSITY SCORE; PROSTATE CANCERS;

CARDIOLOGY; DISEASES; FACTOR ANALYSIS; ONCOLOGY; PATHOLOGY; RADIOTHERAPY; TABLE LOOKUP;

DISEASE CONTROL;

ANTIANDROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CAUSE OF DEATH; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; CONGESTIVE HEART FAILURE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMEDIATE RISK PATIENT; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; PROSTATE CANCER; RISK FACTOR; SCORING SYSTEM; TREATMENT OUTCOME;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; CAUSE OF DEATH; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MYOCARDIAL INFARCTION; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84857914524     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.04.067     Document Type: Article

References (20)

1. M. Bolla, D. Gonzalez, and P. Warde Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin N Engl J Med 337 1997 295 300
2. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
3. McGowan DG, Jones CU, Hunt D, et al. Short-term endocrine therapy prior to and during radiation therapy improves overall survival in patients with T1b-T2b adenocarcinoma of the prostate and PSA ≤20: Initial Results of RTOG 94-08. American Society for Therapeutic Radiology and Oncology 2009 Annual Meeting Proceedings, 2009.
4. P.J. Saylor, and M.R. Smith Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer J Natl Compr Cancer Network 8 2010 211 223
5. M.R. Smith, H. Lee, and D.M. Nathan Insulin sensitivity during combined androgen blockade for prostate cancer J Clin Endocrinol Metab 91 2006 1305 1308
6. N.L. Keating, A.J. O'Malley, and S.J. Freedland Diabetes and cardiovascular disease during androgen deprivation therapy: Observational study of veterans with prostate cancer J Natl Cancer Inst 102 2010 39 46
7. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
8. A.V. D'Amico, J.W. Denham, and J. Crook Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
9. A. Nanda, M.H. Chen, and M.H. Braccioforte Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
10. The NCCN Clinical Practice Guidelines in Oncology PROSTATE CANCER (Version 1.2010) 2010 National Comprehensive Cancer Network Fort Washington, PA
11. D.R. Cox Regression models and life-tables J Royal Stat Soc Ser B Methodol 34 1972 187 220
12. C.D. Newgard, J.R. Hedges, and M. Arthur Advanced statistics: The propensity score - a method for estimating treatment effect in observational research Acad Emerg Med 11 2004 953 961
13. E.L. Korn, B.I. Graubard, and D. Midthune Time-to-event analysis of longitudinal follow-up of a survey: Choice of the time-scale Am J Epidemiol 145 1997 72 80
14. E.L. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Statist Assoc 53 1958 457 481
15. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170
16. J.A. Efstathiou, K. Bae, and W.U. Shipley Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31 J Clin Oncol 27 2009 92 99
17. M. Roach 3rd, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
18. A.V. D'Amico, M.H. Chen, and A.A. Renshaw Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer Cancer 113 2008 3290 3297
19. E.M. Horwitz, K. Bae, and G.E. Hanks Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer J Clin Oncol 26 2008 2497 2504
20. J.W. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial Lancet Oncol 6 2005 841 850